Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 16, 2026

Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica

View original at globenewswire.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica Chicago, Jan…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The growth of the smart home healthcare market is strongly influenced by the increasing number of aging individuals who prioritize maintaining independence while managing their health

    80% confidence

  • Approximately 48.9 million households in the United States currently utilize at least one connected health device

    80% confidence

  • Testing, screening, and monitoring products captured a commanding 76.90% share of revenue in the smart home healthcare market in 2024

    80% confidence

  • The growing prevalence of chronic diseases is a major catalyst driving the expansion of the smart home healthcare market

    80% confidence

  • Global shipment volume of wearable health devices reached 487 million in 2024

    80% confidence

  • The global smart home healthcare market was valued at US$ 27.46 billion in 2024 and is estimated to surpass a market size of US$ 194.51 billion by 2033 at a CAGR of 24.3% during the forecast period 2025–2033

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Smart Home Healthcare Market Outlook 2025-2033: Analysis of Growth Drivers, Constraints, Opportunities, and Trends | Astute Analytica — Source | Via News | ViaNews EU